<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01844427</url>
  </required_header>
  <id_info>
    <org_study_id>2013P000520</org_study_id>
    <nct_id>NCT01844427</nct_id>
  </id_info>
  <brief_title>Memantine Monotherapy for Executive Dysfunction and ADHD</brief_title>
  <official_title>Memantine Monotherapy for Executive Dysfunction and ADHD: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 12-week clinical trial evaluating the efficacy and safety of memantine
      hydrochloride (Memantine HC1, brand name Namenda) in the treatment of executive function
      deficits (EFDs) in adults with Attention Deficit Hyperactivity Disorder (ADHD). After
      screening procedures, memantine is prescribed in randomized, double-blind fashion (equal
      chance of medication or placebo) for 12 weeks.

      The investigators hypothesize that memantine hydrochloride will prove to be an effective,
      safe, and well-tolerated agent for the treatment of EFDs in individuals with ADHD interested
      in non-stimulant medications.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>July 2013</start_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Brief-A Self-Report</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>ADHD</condition>
  <condition>Executive Function Deficits (EFD's)</condition>
  <arm_group>
    <arm_group_label>Memantine HCl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Memantine administered in capsule form twice daily for 12 weeks and titrated up to a maximum daily dose of 20mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Masked placebo administered in capsule form twice daily for 12 weeks. Placebo titration will be titrated according to the same procedure as active memantine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Memantine</intervention_name>
    <description>Memantine HCl is an NMDA antagonist currently FDA approved for the treatment of moderate to severe Alzheimer's-type dementia.</description>
    <arm_group_label>Memantine HCl</arm_group_label>
    <other_name>Namenda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female adults ages 18-45 years;

          2. a diagnosis of DSM-IV [78] ADHD-combined type

          3. a score of at least 20 on the AISRS (a score of 20 in the AISRS identifies subjects
             with at least moderate severity of symptoms);

          4. a BRIEF-A Global Executive Composite T-score of &gt;6; and

          5. proficiency in English. -

        Exclusion Criteria:

        1) Pregnant or nursing females; 2) investigator and his/her immediate family (spouse,
        parent, child, grandparent, or grandchild); 3) any serious, unstable medical illness
        including hepatic, renal, gastroenterological, respiratory, cardiovascular (including
        ischemic heart disease and hypertension), endocrinologic, neurologic, immunologic, or
        hematologic disease; 4) hypersensitivity to memantine; 5) multiple adverse drug reactions;
        6) current or past history of seizures; 7) any history of a major psychiatric disorder
        including schizophrenia, psychosis, bipolar disorder (BPD), or autism spectrum disorder
        (ASD); 8) meets DSM-IV criteria in the last month for major depression or any major anxiety
        disorder or has a Hamilton Rating Scale for Anxiety (HAM-A) or Hamilton Rating Scale for
        Depression (HAM-D) score greater than 14; 9) meets DSM-IV criteria for substance abuse or
        dependence in the last month or has a positive drug urine screen; 10) judged to be at
        serious suicidal risk; 11) use of any other concomitant medication with primarily central
        nervous system activity; or 12) IQ &lt; 80.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2013</study_first_submitted>
  <study_first_submitted_qc>April 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2013</study_first_posted>
  <last_update_submitted>September 23, 2013</last_update_submitted>
  <last_update_submitted_qc>September 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Joseph Biederman, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>ADHD</keyword>
  <keyword>Executive function deficits</keyword>
  <keyword>Psychiatry</keyword>
  <keyword>Psychopharmacology</keyword>
  <keyword>Namenda</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Memantine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

